Drug
Xl184
Xl184: highest development phase Phase 2, developed by Exelixis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Exelixis
Trials
| Drug | Phase | Indication |
|---|---|---|
| XL184 NCT00704288 | Phase 2 | Glioblastoma Multiforme |
Latest
No recent events.
Follow Xl184 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.